COVID Meds Like Paxlovid Will Soon Have Big Price Tags
Medically reviewed by Drugs.com.
By Cara Murez HealthDay Reporter
MONDAY, Oct. 30, 2023 -- Americans have been getting COVID treatments such as Paxlovid for free, but that’s about to end.
The medications will enter the private market this week, the Associated Press reported.
The price for a five-day course of Paxlovid, made by Pfizer, will be $1,390.
Merck has not confirmed a price for its COVID treatment, Lagevrio, but told the AP that it will offer the treatment free to patients “who, without assistance, could not otherwise afford the product.”
The pills will still be available at no cost until those bought earlier by the federal government run out at pharmacies, hospitals and doctor’s offices, according to U.S. Health and Human Services officials. The government paid Pfizer $5 billion for 10 million courses of Paxlovid in 2021.
Once those are gone, those with private insurance may notice a co-pay charge, the AP reported.
People on Medicaid, Medicare or without medical insurance will not pay any out-of-pocket costs for these treatments through 2024, and Pfizer will offer co-pay assistance for Paxlovid through 2028.
The Department of Veterans Affairs, the Department of Defense and Indian Health Service will still have access to government stores of Paxlovid, the AP reported.
The federal government will also keep 1 million treatment courses in its stockpile.
“Pfizer is committed to a smooth commercial transition and is working collaboratively with the U.S. government and health care stakeholders to ensure broad and equitable access to this important medicine for all eligible patients,” the company told the AP.
Medical suppliers can begin ordering the treatment from the drug companies starting this week.
The U.S. Food and Drug Administration granted full approval to Paxlovid earlier this year. It’s meant for adults with COVID who have a high risk of hospitalization or death, including older adults and those with chronic conditions such as obesity, diabetes or asthma.
Sources
- Associated Press
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Further Support and Information on COVID-19
Read this next
Climate Change Could Be Good News for Viruses Like COVID
MONDAY, April 29, 2024 -- Climate change -- and closed windows -- could be aiding the spread of airborne viruses like the one that causes COVID-19, a new study...
Pandemic Had Only Minor Effect on Young Kids' Development
MONDAY, April 22, 2024 -- The pandemic caused only “modest” delays in developmental milestones for infants and toddlers, a new study has found. Previous research has...
Dozens of COVID Virus Mutations Arose in Man With Longest Known Case
FRIDAY, April 19, 2024 -- An immune-compromised man with a year-and-a-half-long COVID infection served as a breeding ground for dozens of coronavirus mutations, a new study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
